Advertisement

Topics

GSK presents new Phase III data on candidate shingles vaccine Shingrix

11:52 EDT 21 Jun 2017 | thePharmaLetter

GlaxoSmithKline is releasing new results from a clinical study showing that its candidate vaccine for…

Original Article: GSK presents new Phase III data on candidate shingles vaccine Shingrix

NEXT ARTICLE

More From BioPortfolio on "GSK presents new Phase III data on candidate shingles vaccine Shingrix"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...